Qure.ai Appoints Darren Stephens as Head of European Operations to Support Growth Plans

  • Drawing on Stephens’ in-depth knowledge Qure.ai is looking to show how AI can dramatically improve diagnostic pathways.

Qure.ai, one of world’s leading providers of AI for healthcare, has appointed Darren Stephens as Senior Vice President & Commercial Head UK and Europe to support the company’s ambitious expansion plans in the United Kingdom and Europe. While adoption of artificial intelligence (AI) in fields such as medical imaging is in the early stages across Europe, Qure.ai has seen growing acceptance among medical professionals of AI as a critical tool to alleviate workloads and address backlogs in diagnosing patients. 

Darren brings a wealth of experience gained from working in pharmaceuticals, infection prevention, point of care, diagnostics and managed services across both pathology and imaging to deliver solutions across Europe including the UK’s National Health Service (NHS) and Ireland’s Health Service Executive (HSE).  

We have ambitious plans to grow the business in the next 12 months and are delighted to bring Darren on board to lead the European business,” said Prashant Warier, Founder and CEO, Qure.ai. “Darren joins us at a very exciting time for the company. With medical professionals across the region urgently needing to address backlogs in diagnostic pathways and improve the outcomes for patients, they are becoming more and more receptive to the potential of AI to speed up the reading and analysis of medical images.

Before joining Qure.ai, he was the Country Manager, UK and Ireland for Everlight Radiology Ltd, one of the fastest growing global teleradiology companies in the market, where Darren was responsible for the company’s commercial and implementation activities. Prior to that role, Darren led Core Laboratory & Point of Care Solutions for Roche in Ireland focused on disease areas including Oncology, Cardiac, Women’s Health, Bone, Infectious Diseases, Critical Care, all Lab Clinical Chemistry and Immunoassay Testing Systems. In Darren’s early career he also held roles at Ecolab and Pfizer in Ireland with responsibilities for sales and key account management. 

The team at Qure have done an outstanding job bringing the solutions developed to date to clients and patients that need them the most. I look forward to building on this collective success and expanding our team to show the benefits of AI to medical professionals and ultimately help to improve diagnostic pathways for patients,” added Darren Stephens, SVP and Commercial Head UK & Europe, Qure.ai. 

Qure.ai appoints Dr. Shibu Vijayan as Medical Director – Global Health

The new posting reiterates Qure.ai's efforts to strengthen its strategic offerings and accelerate global expansion in the public healthcare sector. 

Qure.ai, a leading health tech provider, has appointed renowned global health expert, Dr. Shibu Vijayan as its Medical Director for Global Health Practice. The company enjoys clear leadership in the global health space and the new addition of Dr Vijayan to its helm will bolster its partnerships with strategic change-makers in public health, manifold.  

Dr. Vijayan is a senior clinician in Community and Public Health Services. He has 25 years of experience in developing, monitoring, and evaluating public health projects, including developing healthcare-related proposals in both private and not-for-profit organizations. He is also an accredited International general Tuberculosis (TB) expert by the TB team hosted by WHO and Stop TB Partnership.

Prior to Qure.ai, he was at PATH and has also worked with the WHO as Technical Consultant for the TB Control Program in India and was associated with Medicines Sans Frontiers (MSF, Netherlands) as a field Epidemiologist in Ethiopia.

Commenting on the announcement, Prashant Warier, Founder and CEO, Qure.ai, said, “Dr. Vijayan comes with an enviable trove of experience, varied across the public health spectrum. He has been one of our long-standing supporters and was one of the first people to adopt qXR for TB in the Global Health community. We are delighted to welcome him as one of our own and continue our journey to improve healthcare outcomes for disadvantaged populations globally. With him at the helm of our global health portfolio, I am positive that Qure.ai will strengthen our leadership position in the application of AI solutions to deliver affordable and accessible healthcare for everyone". 

“Qure’s AI and digital solutions are targeted towards accelerating Universal Health Coverage. This dynamic team is doing stellar work towards improving global healthcare access and I am excited to be part of the journey. We will continue to strive towards optimizing global health practices and expand our footprint further to reach remote communities and their unmet medical needs”, said Dr Shibu Vijayan, Medical Director, Global Health, Qure.ai. 

Qure.ai's global health presence has been on a steady growth path. The company has increased its impact manifold during the last two years and has touched over 12 million lives across the world’s most vulnerable populations. Qure.ai's intervention during the pandemic and the continued efforts to optimize lung health screening in vulnerable communities has been a distinguisher across markets.   

The company is one of the leading AI solutions providers to be recommended by WHO, in the absence of a human reader. Qure.ai is present in 600+ sites across 60+ countries, including the UK, US, Southeast Asia, Latin America, Australia, and Africa.  

Qure.ai and Erasmus MC Launch AI Innovation Centre for Medical Imaging

Leading health tech firm Qure.ai has partnered with Erasmus MC, University Medical Center Rotterdam, to launch the AI Innovation Lab for Medical Imaging. The initial program will run for 3 years and will conduct detailed research into the detection of abnormalities by artificial intelligence (AI) algorithms for infectious and non-infectious disease conditions. The goal will be to understand the potential use cases for AI in Europe and provide guidance to clinicians on best practices for the adoption of the technology specifically for their requirements.

Erasmus MC is recognised as a leading innovator in healthcare, pursuing excellence through research and teaching. It will run the Lab, conducting research projects using Qure’s AI technology. The initial research project will focus on musculoskeletal and chest imaging.

“We are delighted to be partnering with Qure.ai, as we see the adoption of AI in healthcare at a critical juncture, where clinicians are asking for expert advice on how best to evaluate the adoption of the technology. In Qure's work to date, it is clear they have gathered detailed insights into the effectiveness of AI in healthcare settings, and together we will be able to assess effective use cases in European clinical environments" said Dr. Jacob J. Visser, Radiologist, Chief Medical Information Officer, and Assistant-Professor, Value-based Imaging, at Erasmus MC. 

Healthcare systems across Europe have faced financial pressures due to the pandemic. Resources are constrained as it is a challenge to recruit specialist consultants and radiologists. Adopting AI can alleviate clinicians' burden and provide adequate early warning systems and ongoing monitoring of abnormalities. Qure is already seeing benefits of automated detection of anomalies and progressive detection where AI can provide a more accurate and efficient analysis of tumours.

“Our work to date worldwide has shown many examples of where AI can prove invaluable to clinicians and patients. Our work with Erasmus MC is a critical part of our commitment to provide European clinicians with the validation and best practice they need to give them the confidence to adopt AI. Furthermore, given their global reputation in research for medical imaging and diagnostics, we look forward to producing robust and insightful analysis on the role of AI in European healthcare settings with the team at the AI Innovation Lab for Medical Imaging" said Prashant Warier, CEO and Founder, Qure.ai.

Over 3 years of the partnership, multiple radiologists and PhD students will work in the AI innovation centre to generate evidence and publish them in peer-reviewed journals. The team will focus on AI for Chest CTs, X-rays and brain CTs.

Qure's technology is used in over 500 healthcare facilities in 50 countries. It has successfully run ground-breaking initiatives in remote medical diagnostics, such as its mobile medical van programme for Tuberculosis(TB) in Africa, India and Southeast Asia. It is working with Astra Zeneca to integrate innovative artificial intelligence (AI) solutions for the early detection of lung cancer. In addition, Qure has always invested in strong collaborations with premier academic institutes globally, which have helped independent validations of the performance of their algorithms.

Fujifilm and Qure.ai join hands with IHVN to accelerate TB screening in rural Nigerian Communities

  • Fujifilm’s Xair ultra-portable handheld, battery powered X-ray machine will be deployed with Qure.ai’s AI-enabled Chest X-ray solution to screen presumptive TB cases
  • The partnership is aimed at augmenting active screening for TB in hotspots with the support of USAID and the Lagos State TB program.

The Institute of Human Virology in Nigeria (IHVN) has announced their partnership with Fujifilm, the multinational medical imaging device manufacturers and Qure.ai, a global AI-enabled medical imaging solutions provider to use advanced technology to help optimize tuberculosis (TB) screening outreach in Nigeria. The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.

TB is the leading cause of death in Sub-Saharan Africa (Nigeria inclusive) and the most common opportunistic co-infection alongside HIV. Fujifilm’s Xair portable Xray device powered by the Qure.ai’s artificial intelligence algorithm provides an ideal solution for rural mass testing programs, offering ultra-portability, high accuracy, and efficiency point-of-care diagnostic solutions. 

Dr. Chukwuma Anyaike, Director and National Coordinator, National Tuberculosis, Leprosy and Buruli Ulcer Control Program – Federal Ministry of Health NIGERIA, said; “The successful piloting of the use of portable digital x-ray from Fujifilm with Qure Ai technology by IHVN in collaboration with NTBLCP, Federal Ministry of Health Nigeria has proven its positive impact on case detection of tuberculosis."

Commenting on the partnership, Dr Aderonke Agbaje, Chief of Party USAID TB-LON 3 Project at Institute of Human Virology Nigeria said: “IHVN is at the forefront of battling TB and correlated infections using innovative solutions to optimise care delivery. Through our efforts (rural dwellers in communities with difficult terrains have been reached with TB care). Our partnership with Fujifilm and Qure.ai for AI enabled TB screening is our most recent initiatives towards community outreach. We look forward to scaling active case finding efforts and improving patient care."

The United States Agency for International Development (USAID) is working with IHVN to rapidly increase the level of TB cases detected and treated in Nigeria over the next five years. The project aims to improve access to high-quality, patient-centric treatment for TB, including drug-resistant tuberculosis and co-infections with HIV, which is common in the community. The project also covers contact tracing of TB presumptive cases to curb contagion and bring more cases under the aegis of the national TB reporting system. IHVN is the implementing partner for the project that covers the states of Lagos, Osun, Ogun, and Oyo.  

Commenting on the development, Godspower Asika, National Sales Manager – Nigeria, Fujifilm Middle East & Africa, said “We are happy to note that IHVN is screening numerous communities in Nigeria with our ultra-portable x-ray machine, the Fujifilm FDR Xair, which is integrated with AI technology from Qure Ai. We applaud the Federal Ministry of Health of Nigeria's NTBLCP leadership for working kindly with IHVN to accomplish this, and Fujifilm will continue to make its technology available to all partners and stakeholders.”

Fujifilm FDR Xair is a battery-powered, ultralight, and compact X-ray device that can function for hours without electricity. FDR Xair, coupled with Qure.ai’s Al-powered radiological image analysis allows for accurate screening & detection of lung abnormalities, and presumptive TB even in the remotest parts of the world and can be beneficial in expediting the process of TB diagnosis at the point of care.

Commenting on the partnership, Prashant Warier, CEO and Founder, Qure.ai said; “We are excited to partner with Fujifilm on this project to combine two state-of-the-art technologies for the greater communal good. Our AI enabled chest X-ray solution, qXR, has been evaluated by WHO and meets their criteria for TB triage and screening in the absence of a human reader. IHVN’s Nigeria project will help reinforce what superior technology can do for universal lung health and healthcare access for everyone.”

Qure.ai's chest X-ray software can detect multiple lung abnormalities within a minute. It can accurately assess radiological findings suggestive of a host of diseases, including pneumonia, COPD, TB, and Heart Failure, among others.

Together IHVN, Fujifilm and Qure aim to strengthen the systems and structures for tuberculosis detection,treatment, and notification in rural Nigeria. The partnership will help in reducing the transmission and progression of tuberculosis and aid in accelerating tuberculosis research and innovation to improve the quality of programs implemented.

Qure.ai adds Impact Investor TEAMFund LP to its Series C funding round

Qure.ai, a leading healthcare AI solution provider, has added TEAMFund LP to its series C funding round. With this, Qure.ai joins the Fund I Portfolio Companies of the impact investor fund.  

The additional capital supplements the funding secured by Qure.ai earlier this year, in a round led by three leading life science investor companies – Novo Holdings, HealthQuad, and Merck Holdings, and supported by existing investor Mass Mutual Ventures. Other current investors include Sequoia Capital and Fractal Analytics. 

TEAMFund believes that improving global healthcare access and quality starts where the need is greatest. The company extensively supports med-tech and digital health startups that are working towards increasing access to sustainable healthcare solutions that can address unmet needs in resource constrained populations. Fund I is especially focused on companies working towards alleviating high-impact healthcare burdens with digital-first solutions.  

Yousuf Mazhar, Managing Partner at TEAMFund said “We are very excited to join Qure.ai and an amazing team as they advance their market leading AI technology in multiple imaging applications. Qure’s AI imaging platform has already demonstrated that it can detect multiple anomalies and nodules in the chest which can lead to early identification of lung cancer, which is the most common form of cancer worldwide.  In this way alone, Qure can have immense impact worldwide.”     

 Qure.ai will use the funding to extend and strengthen its global reach and intensify product development for critical care and community diagnostics. Qure.ai’s global health presence has been on a steady growth path. The company’s intervention during the pandemic and the continued efforts to optimise lung health screening in vulnerable communities has been a distinguisher for global health across markets.  

Commenting on the funding, Prashant Warier, CEO and Co-founder, Qure.ai said: “TEAMFund’s sharp focus on fashioning a sustainable approach to improving healthcare quality and access aligns with Qure’s mission of making quality healthcare accessible and affordable to all. This fresh infusion of funds strengthens Qure.ai’s position as a global leader in healthcare AI and is a force-multiplier in our effort towards building equitable healthcare solutions for all. Moreover, with regulatory clearances for our products in 75+ countries (including FDA & CE), we are optimally positioned to scale non-linearly across global markets”. 

Qure.ai is present in 600+ sites across 60+ countries including UK, US, Southeast Asia, Latin America, Australia and Africa. 

Centre for Infectious Disease Research in Zambia (CIDRZ) Partners with Qure.ai for TB Screening

The Centre for Infectious Disease Research in Zambia (CIDRZ) announced its partnership with Qure.ai, a leading health-tech firm that builds artificial intelligence (AI) powered medical imaging diagnostics solutions, to implement comprehensive tuberculosis (TB) screening in Zambia. The project will have Qure.ai’s AI-enabled computer-assisted detection software, along with its lung health management platform, to evaluate chest X-rays and identify presumptive TB patients.

Supported by the U.S. Centers for Disease Control and Prevention (CDC) through a cooperative agreement with CRDF Global, Qure.ai working with CIDRZ, will integrate its lung health suite – qXR, AI-enabled chest x-ray solution along with qTrack, a comprehensive case management platform to help optimize radiology workflows in 7 hospitals in Zambia.

CIDRZ CEO, Dr. Izukanji Sikazwe said “CIDRZ welcomes this partnership as the qXR solution will contribute immensely to Zambia’s stride to ending TB by the year 2030. With use of the qXR solution for Chest X-rays, we anticipate an increase of TB detection and monitoring in the various health facilities in the country”.

The sites include Kanyama, Chawama, Matero, Choma, and Kafue General Hospitals, Monze Mission Hospital, and Livingstone University Teaching Hospital. The project will launch across these seven sites, with a mix of analogue and digital X-rays used to screen for TB presumptive cases.

Speaking about this partnership, Prashant Warier, Founder and CEO, of Qure.ai said, “We are excited to be partnering with CIDRZ in their efforts to curb TB and take significant strides towards universal lung health in the country. Our solutions will be crucial in bringing quality diagnostic healthcare to thousands of people in Zambia. I also want to laud Stop TB Partnership and CDC for supporting this technology-driven initiative that will undoubtedly help CIDRZ in their endeavor to eradicate TB from the community.”

Qure.ai’s lung health suite of products will complement the existing screening and diagnostic pathways and enable a sustained increase in TB case detection in high-burden settings. The AI-enabled screening program will be crucial for augmenting the current TB screening mechanism and alleviate pressure on the healthcare workforce relative to identification of TB presumptive patients. ure.ai’s CE-approved chest X-ray software – qXR, can detect 30 critical lung abnormalities in under a minute. It can accurately detect clinically relevant findings suggestive of a host of lung diseases over and above TB, such as Pneumonia, COPD, COVID-19, and Silicosis, among others.

Unilabs signs on Qure.ai for triaging chest X-rays

Unilabs, the leading diagnostic services provider, has announced a partnership with Qure.ai, a market leader in medical artificial intelligence (AI) solutions. Through this partnership, Unilabs will be deploying Qure.ai's AI solution to aid in the classification of chest X-rays into normal and abnormal exams. The solution will initially be implemented and piloted in Unilabs TMC's Elective UK Service arm to help increase the capacity and optimise radiology workflow.

This is yet another important milestone of the Unilabs AI Centre of Excellence and a testimony of our efforts to continue to implement AI solutions and futureproof our radiology business,” said Unilabs Chief Medical and Operations Officer Dr Christian Rebhan.Qure.ai's AI-enabled chest X-ray solution will aid us in the triaging of incoming cases, reducing the reading time for unremarkable chest X-rays by 25 to 50%.”

Qure.ai's CE-certified chest X-ray solution, qXR, will help identify which cases are clear of clinically relevant findings, allowing radiologists to detect them even before they open the case. Approximately, 50% of the chest X-rays are unremarkable and need to be completed quickly so the radiologists can free up capacity and focus their attention to those exams that have relevant findings.

Speaking about the partnership, Prashant Warier, CEO and Founder of Qure.ai, said, “As an early adopter of AI tools in Emergency Radiology, Unilabs’ TMC has already established clear dominance in the segment. We are excited to work with a global leader striving to bring out the best in health tech. We consider the EU among our crucial markets for the company and see immense potential in our partnership with Unilabs to scale new heights in the field of AI for teleradiology across the region. This partnership will reinforce our presence in the UK and will mark ourexpansion into other European regions."

Qure.ai's chest X-ray software can detect multiple lung abnormalities in under one minute. It can accurately assess radiological findings suggestive of a host of lung diseases, including pneumonia, COPD, TB, and heart failure, among others.

Qure.ai Announces Appointment of Amit Kakar and Charles-Antoine Janssen to its Board of Directors

  • The company has also added Navjeewan Khosla from Novo Holdings and Ajay Mahipal from HealthQuad as Board Observers 

  •  

    Novo Holdings and HealthQuad had led Qure.ai’s Series C funding for $40 Million in March 2022 

 

Qure.ai, one of the leading health tech firms using Artificial Intelligence (AI) for medical imaging diagnostics, has announced the appointment of two new members to its Board of Directors. Joining the team at the helm are Dr. Amit Kakar MD, from Novo Holdings and Mr. Charles-Antoine Janssen, Chief Investment Officer, HealthQuad. The announcement comes on the heels of Qure.ai’s $40 million funding round led by Novo Holding and HealthQuad in March 2022. They have also appointed Mr. Navjeewan Khosla, Principal, Novo Holdings and Mr. Ajay MahipalMahipal, Director, HealthQuad, as Board Observers.  

 

Dr. Amit Kakar is Senior Partner, Head of Novo Holdings Asia, and a healthcare professional with over 30 years of experience across key verticals including Medical Technology, R&D, Manufacturing, Pharma Retail, Drug Discovery, Clinical Research, Biotech, Hospitals and Diagnostic Centers, Primary and Specialty Care Centers, among others. His diverse experience also encompasses investing, operational and management roles across health-tech companies. He is currently part of the Board of Directors of Singapore-based life science company, ESCO, and telemedicine portal – Doctor Anywhere. As a senior partner, Dr. Kakar’s invaluable expertise can help Qure scale global markets. 

 

Novo Holdings is a world-leading healthcare and life sciences investor with a focus on creating long-term, sustainable value. Headquartered in Copenhagen, Denmark, with offices in San Francisco, Boston, London and Singapore, Novo Holdings has a portfolio of more than 150 companies.  

 

Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Asia said, “I am passionate about diagnostic imaging which is being transformed by machine learning and real-world data. Qure is in the forefront of that change in providing affordable and accessible healthcare to patients across the globe. I am looking forward to working closely with the team and my fellow board members on this next exciting phase of Qure.ai’s journey.”  

 

Commenting on the occasion, Navjeewan Khosla , Principal, Novo Holdings said that; “We are very excited to partner with Prashant and his team at Qure.ai. Healthcare innovation, especially for developing economies, is a critical aspect that can help rewrite the current narrative. With technological intervention and intelligent solutions, we believe that quality healthcare can be made acessible and affordable to all. Qure.ai’s vision for its future is in perfect agreement with that and I look forward to working together to achieve new heights of success for all of us.” 

 

 

Charles-Antoine Janssen is the Chief Investment Officer at HealthQuad and the Co-Founder & Managing Partner at KOIS S.A., a global impact investing firm. HealthQuad is a joint venture between KOIS S.A. and Quadria Capital, with an exclusive focus on the Indian health-tech market. Charles-Antoine has over 26 years of industry experience and is a well-versed impact investor focused on healthcare access. His vision to nurture innovative models that can transform healthcare, is in perfect alignment with Qure’s vision to use AI and make quality healthcare accessible to all. Charles-Antoine serves on the board of Medikabazaar, THB, Lilac Insights, TC4AI, Regency Hospitals, GoJob, the Climate School and Potential Project, and on the Advisory Board of Lighthouse (India PE fund) and Quadria (Asia healthcare PE fund). He is also a member of the board and audit committee of UCB, as well as a board member of Tubize (UCB’s listed reference shareholder). 

  

HealthQuad is India’s leading digital health-focused venture capital fund, with assets under management of USD 200 Mn across two funds. Its focus is to nurture innovative models which radically improve healthcare access and affordability by leveraging technology. 

 

Charles-Antoine Janssen, Chief Investment Officer, HealthQuad said; “India’s healthcare market is at an inflection point, with digital healthcare solutions front-ending the disruption. Technology-led healthcare is the most promising sunrise sector in the country, forecasted to race ahead at a CAGR of 26 per cent to $21bn by 2025. We are focused on partnering with innovators who can help bridge gaps in the access to quality healthcare for rural and semi-urban communities without adding to their financial burden. Qure.ai is an ideal springboard to take our vision to the next level with their AI-powered imaging technologies, that impact 4 mn lives annually and are deployed across the public health spectrum in 50+ countries. I am looking forward to being part of Qure’s next phase of growth to make quality healthcare an affordable reality for all.” 

 

Commenting on his new position as Board Observer, Ajay Mahipal, Director, HealthQuad said that; It is the need of the hour to foster innovations that can radically change the means in which quality healthcare is made accessible to all. We at HealthQuad are particular to partner with companies and innovators who are making a difference and we could not be happier to welcome Qure.ai to our midst. I am elated to be part of Qure, a company that has been continuously scaling up and addressing the accessibility and affordability quotient for healthcare through its innovative products. It will be an honor to be part of the esteemed board of directors and weigh in on Qure’s global growth roadmap.” 

 

Qure.ai is poised for accelerated global growth and foray into new markets. The new members of the board will be crucial in guiding the organization in scaling up aggressively. They will also be instrumental in extending and strengthening Qure.ai's global reach, especially in the US and European markets, and intensifying product development for critical care and community diagnostics.    

 

Commenting on the new appointments, Prashant Warier, CEO and Founder, Qure.ai said that “We are delighted to welcome Dr Amit and Mr. Charles-Antoine to our esteemed board of directors. We are equally elated to have Mr. Navjeevan Khosla and Mr. Ajay Mahipal join us with their unique perspectives, stemming from their extensive experience in the healthcare industry. They have joined us at a key/crucial juncture in our company’s growth. We strongly believe that their collective experience in leading global health-tech companies will be a great advantage to Qure, as we gear up for massive global growth. We are excited to have newer perspectives added to our board of directors and is looking forward to making quality healthcare accessible to all.” 

 

Dr. Amit Kakar and Charles-Antoine Janssen join Anandamoy Roychowdhary of Sequoia India, Ryan Collins of MassMutual Ventures, and Srikanth Velamakanni, and Satish Raman from Fractal Analytics Private Limited alongside Prashant Warier, CEO and Founder, Qure.ai. The new appointments are effective immediately.  

 

USAID-supported SAMRIDH Healthcare Blended Finance Facility supports Qure.ai to strengthen India’s healthcare systems

The financial assistance will help Qure.ai expand its artificial intelligence solution to screen for lung diseases across 15 states in India

The SAMRIDH Healthcare Blended Financing Facility, supported by the U.S. Agency for International Development (USAID) and implemented by IPE Global, has committed 2.45 Crore INR ($350,000 USD) to Qure.ai to scale Artificial Intelligence (AI)-enabled chest X-ray screening software, qXR, in 50 sites across more than 15 Indian states. The software will enable healthcare workers in the dual screening of COVID-19 and lung diseases such as Tuberculosis, in remote and resource-challenged locations, and will benefit an estimated 62,500 people in the next 12-14 months.

Qure.ai is a leading health-tech firm that builds AI-powered solutions focusing on pulmonary and neurocritical care to deliver better patient outcomes. Qure.ai’s CE-approved qXR software not only detects 30 critical lung abnormalities in under a minute but can also quantify the infection, giving healthcare workers real-time insights into disease progression. As a result, it provides instant diagnostic support and actionable insights for frontline healthcare workers while optimizing resources and strengthening community care.

The USAID-supported SAMRIDH Blended Finance Facility, through partnerships with organizations including Qure.ai, aims to advance its mission to scale market-based solutions and build sustainable and resilient healthcare systems for India. SAMRIDH offers both grant and debt financing provision to healthcare enterprises and innovators to improve their capacity for production and supply of high-impact health solutions that can be scaled rapidly to meet health challenges posed by the pandemic and future crises. This is complemented with a strong technical assistance and capacity building component, enabling enterprises to unlock new sources of capital through blended financing solutions, while ensuring long-term sustainability and expansion.

Speaking about this partnership, Mr. Himanshu Sikka, Project Director, SAMRIDH said, “We welcome the opportunity to support Qure.ai in expanding its AI-led solution to detect COVID-19 and lung diseases. It is faster, accurate, cost-effective, and will truly transform diagnostics in primary healthcare settings. Through this collaboration, we reinforce our commitment to drive greater investments in market solutions that combine technology and innovation to improve access to quality and affordable healthcare services for vulnerable populations.”

 

Prashant Warier, CEO and Founder of Qure.ai said, “We are pleased to receive this support from USAID and IPE Global Limited. Our AI technology for chest X-ray screening and interpretation can better the lives of patients and medical personnel. Remote locations in India struggle for resources to deal with highly transmissible infectious diseases like Tuberculosis and COVID-19. Our AI solution will significantly improve diagnosis, treatment, and patient health. I believe it can pave the way for the deployment of advanced healthcare solutions in more public health settings.”

Qure.ai raises $40 Million from healthcare investors Novo Holdings and HealthQuad

The funding will accelerate the AI-driven healthcare company’s market expansion into the global market and support new product development   

We are happy to announce that we have secured $40 million in a funding round led by Novo Holdings and HealthQuad, supported by existing investor Mass Mutual Ventures. We will use the new investment to extend and strengthen our global reach, especially in the US and Europe, and intensify product development for critical care and community diagnostics.

We have created a niche for ourselves with advanced technology that reads and interprets medical images like X-rays, CTs, and Ultrasounds in less than a minute, making equitable and high-quality healthcare a reality across the globe. Our AI solutions are FDAapproved, CEcertified, and evaluated by the World Health Organization.

Our automated medical imaging tools can shorten the time to diagnosis while enabling physicians to triage medical cases more effectively, especially in time-sensitive situations. This helps healthcare providers identify critical scenarios within minutes — versus hours — to avert fatalities and improve the quality of patient care. In other settings, where adequate, skilled specialists may not be available, our technology is used as the first level of screening for many infections and non-communicable

Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia, said: “We are very pleased to join the outstanding team at Qure.ai and to contribute to their efforts of providing world-class AI solutions in the imaging space, for the benefit of patients worldwide. Qure.ai is at the forefront of transforming diagnostics in both acute and chronic ailments, which is fully aligned with our mission of advancing high-quality and accessible healthcare using innovation and digitization. Further, we are excited to connect Qure.ai to our portfolio partners as we see several promising synergies.”

Novo Holdings is a worldleading healthcare and life sciences investor with a focus on creating long-term, sustainable value. Headquartered in Copenhagen, with offices in San Francisco, Boston, London, and Singapore, Novo Holdings has a portfolio of more than 150 companies.  

Charles – Antoine Janssen, Chief Investment Officer, HealthQuad said: “We are thrilled to be part of the Qure team. Their world-class AI technologies adhere to the most stringent international standards, and have made high-quality, accessible care a reality. We remain committed to collaborating with innovative firms that work to improve global healthcare infrastructures." 

“It’s no accident that Qure is one of the leading startups thriving in the health tech sector. Through noteworthy collaborations with ministries of health and government entities like the NHS, pharmaceuticals like AstraZeneca, and international advocacy groups like StopTB, amongst others, Qure has already built a network of global commercial partnerships. The pandemic has also accelerated the shift to digital transformation, and we are proud to back their growth,added Ajay Mahipal, Director, HealthQuad.  

HealthQuad is India’s leading digital health-focused venture capital fund with assets under management of USD 200 Mn across two funds. Its focus is to nurture innovative models which radically improve healthcare access and affordability by leveraging technology.

Prashant Warier, CEO and Founder, Qure.ai, said: “Every year our technology helps more than four million people across 50 countries. Our goal is to continue being bullish in our market expansion, especially in the US and Europe. We are committed to aiding healthcare professionals in diagnosing illnesses faster and with more detail and accuracy while automating most of the routine work. This is a win for all involved in healthcare, especially for patients across the globe who will benefit from vastly improved health outcomes.

Ryan Collins, Managing Director, MassMutual Ventures said: “We have been incredibly impressed with Qure’s progress since we first invested over two years ago. The team is exceptional and the progress on product development, now across many different imaging modalities and use cases, as well as global expansion, has been outstanding. We are very happy to continue supporting Qure and welcome Novo and HealthQuad as partners.”